1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,750 | 7,100 | 17:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Eupraxia Pharmaceuticals: Dauerhaftigkeit der EoE-Therapie im Fokus der H.C. Wainwright Konferenz | 1 | Investing.com Deutsch | ||
| Fr | Eupraxia auf der Cantor Healthcare Conference: EoE-Daten und großes Marktpotenzial | 1 | Investing.com Deutsch | ||
| Mi | Eupraxia Pharmaceuticals Inc: Eupraxia begins trading on Nasdaq Global Select | 2 | Stockwatch | ||
| 08.09. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Eupraxia Pharmaceuticals Inc: Eupraxia talks improved EoE symptoms in phase 1/2 trial | 2 | Stockwatch | ||
| 13.08. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients | 333 | GlobeNewswire (Europe) | The number of patients experiencing moderate to severe odynophagia (pain swallowing) in the cohorts analyzed (Cohorts 7-9) was reduced from 62% at baseline to 25% from 24 through to 52 weeks post... ► Artikel lesen | |
| 11.08. | Eupraxia Pharmaceuticals reports Q2 results | 1 | Seeking Alpha | ||
| 11.08. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results | 269 | GlobeNewswire (Europe) | New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI Strengthened executive team and board to bolster... ► Artikel lesen | |
| 11.08. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.07. | Cantor Fitzgerald reiterates Eupraxia stock Overweight rating at $19 | 3 | Investing.com | ||
| 14.07. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints EVPs | 1 | Stockwatch | ||
| 13.07. | Eupraxia names new executives, relocates operations | 1 | Investing.com | ||
| 13.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth | 246 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 08.07. | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints three directors | 1 | Stockwatch | ||
| 07.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.07. | Eupraxia Pharmaceuticals verstärkt Verwaltungsrat mit drei Neuzugängen | 2 | Investing.com Deutsch | ||
| 07.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization | 347 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 25.06. | Oppenheimer initiates Eupraxia stock with Outperform rating | 1 | Investing.com | ||
| 25.06. | Oppenheimer startet Coverage für Eupraxia mit "Outperform"-Rating und hohem Kursziel | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,020 | -3,49 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,020 | -0,68 % | Inovio vor entscheidender FDA-Zulassung: Markteinführung von INO-3107 rückt näher | ||
| INFLARX | 1,810 | -2,11 % | Klinische Daten geben InflaRx NV neuen Schub: Der Weg über 2 EUR | ||
| INTELLIA THERAPEUTICS | 9,830 | -4,38 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,230 | -5,91 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,423 | +9,30 % | Die Hülle entscheidet: Warum NurExone Wirkstoffe in Exosomen verpacken will | ||
| IBIO | 1,015 | 0,00 % | iBio, Inc. - 8-K, Current Report | ||
| GERON | 1,155 | -2,28 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,960 | -3,87 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,400 | -0,80 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,422 | +3,85 % | Myriad Genetics unter Druck: Fokus auf Krebstests soll Wende bringen | ||
| MANNKIND | 3,091 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,148 | +1,05 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,386 | -3,28 % | Stifel reiterates Immunic stock rating on MS drug potential | ||
| EMERGENT BIOSOLUTIONS | 5,550 | +0,36 % | Emergent BioSolutions: Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility |
Das Unternehmen EUPRAXIA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,000 Euro und damit -4,11 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.